Diamandis E P, Yousef G M, Luo L Y, Magklara A, Obiezu C V
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
Trends Endocrinol Metab. 2000 Mar;11(2):54-60. doi: 10.1016/s1043-2760(99)00225-8.
The traditional human kallikrein gene family consists of three genes, namely KLK1 [encoding human kallikrein 1 (hK1) or pancreatic/renal kallikrein], KLK2 (encoding hK2, previously known as human glandular kallikrein 1) and KLK3 [encoding hK3 or prostate-specific antigen (PSA)]. KLK2 and KLK3 have important applications in prostate cancer diagnostics and, more recently, in breast cancer diagnostics. During the past two to three years, new putative members of the human kallikrein gene family have been identified, including the PRSSL1 gene [encoding normal epithelial cell-specific 1 gene (NES1)], the gene encoding zyme/protease M/neurosin, the gene encoding prostase/KLK-L1, and the genes encoding neuropsin, stratum corneum chymotryptic enzyme and trypsin-like serine protease. Another five putative kallikrein genes, provisionally named KLK-L2, KLK-L3, KLK-L4, KLK-L5 and KLK-L6, have also been identified. Many of the newly identified kallikrein-like genes are regulated by steroid hormones, and a few kallikreins (NES1, protease M, PSA) are known to be downregulated in breast and possibly other cancers. NES1 appears to be a novel breast cancer tumor suppressor protein and PSA a potent inhibitor of angiogenesis. This brief review summarizes recent developments and possible applications of the newly defined and expanded human kallikrein gene locus.
传统的人类激肽释放酶基因家族由三个基因组成,即KLK1[编码人类激肽释放酶1(hK1)或胰腺/肾激肽释放酶]、KLK2(编码hK2,以前称为人类腺体激肽释放酶1)和KLK3[编码hK3或前列腺特异性抗原(PSA)]。KLK2和KLK3在前列腺癌诊断中具有重要应用,最近在乳腺癌诊断中也有应用。在过去两到三年中,已鉴定出人类激肽释放酶基因家族的新的假定成员,包括PRSSL1基因[编码正常上皮细胞特异性1基因(NES1)]、编码zym/蛋白酶M/神经丝氨酸蛋白酶的基因、编码前列腺酶/KLK-L1的基因以及编码神经丝氨酸蛋白酶、角质层糜蛋白酶和胰蛋白酶样丝氨酸蛋白酶的基因。另外五个假定的激肽释放酶基因,暂命名为KLK-L2、KLK-L3、KLK-L4、KLK-L5和KLK-L6,也已被鉴定出来。许多新鉴定的类激肽释放酶基因受类固醇激素调节,已知一些激肽释放酶(NES1、蛋白酶M、PSA)在乳腺癌及可能的其他癌症中表达下调。NES1似乎是一种新型的乳腺癌肿瘤抑制蛋白,而PSA是一种有效的血管生成抑制剂。本简要综述总结了新定义和扩展的人类激肽释放酶基因位点的最新进展及可能的应用。